Capital Raised
Publications
Partners
Patents Issued/Pending
OUR VISION
Our next-generation detection technology continuously collects information as blood flows through your brain. Areas of too much or too little blood light up, letting doctors know what’s going on and how to fix it.
We pride ourselves in networking with industry leaders who not only understand the space, but also want to disrupt it. If you are interested in partnering with us or investing, please feel free to send us an email.
CALIFORNIA INSTITUTE OF TECHNOLOGY
FREE FLOW
DigiTx Partners
Our Journey So Far
The milestones that have shaped NeuraNova
We’re proud of the progress that has brought us here. Each step reflects our commitment to advancing neuroscience through technology.
2018
The start of an idea
Shane started as a medical engineering Ph.D. student in Dr. Yu-Chong Tai’s lab at Caltech, where portable stroke detection quickly became his interest and thesis research topic.
2019
Human trials begin
After receiving IRB approval at the Keck Hospital of USC, live human clinical trials were started. The data collected at this stage proved the potential of the technology underlying StrokeDx.
2020
Protection and Validation
Patents surrounding the StrokeDx technology were filed. Although Covid-19 slowed clinical testing, efforts were shifted towards computational analysis of the StrokeDx technology, giving us a better understanding of how (and why) it works.
2020
Meeting NIH Paylines
The StrokeDx technology received a five-year $2.45M grant from the National Institute of Neurological Disorders and Stroke (NINDS) at the NIH funding additional human trials, technological improvements, and software updates.
2021
First-In-Man studies
In May, we published our clinical data showing differentiation and imaging of ischemic and hemorrhagic stroke in real stroke patients. Images produced by the StrokeDx sensor closely mirrored those created through CT imaging.
2022
StrokeDx IS FOUNDED
StrokeDx was founded and successfully raised a $2.3M seed round. These funds will be used for automation of the sensor, software and algorithm improvements, and FDA consultation to ensure we’re taking the most direct route from idea to a product in the hospital.
2023
StrokeDx Accepted Into MedTech Innovator
With a 5% acceptance rate, StrokeDx joins the 2023 cohort of the world's largest medical device accelerator program: MedTech Innovator.
2023
Engineering and IP
StrokeDx received an exclusive license on all relevant IP from Caltech. Subsequently, StrokeDx made strides in engineering and filed additional IP on the next-generation StrokeDx device.
2023
MedTech Innovator
StrokeDx wins the 2023 Global Competition the world’s largest accelerator of medical technology companies. From among 5 finalists the winner was determined by live audience vote during The MedTech Conference, powered by AdvaMed.
2024
StrokeDx Raises $5M
Closed $5M Series Seed positioning the company to further validate and expand its pioneering stroke detection technology. The involvement of leading investors such as DigiTx Partners and Freeflow Ventures underscores the confidence in StrokeDx’s innovative approach to cerebrovascular monitoring.